Lisata Therapeutics Inc. Net Assets
Lisata Therapeutics Inc. net assets. Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has net assets worth $7.99 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.03 Million) and total liabilities ($3.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LSTA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.99 Million |
| % of Total Assets | 72.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -84.13% |
| 10-Year Change | 259.06% |
| Growth Volatility | 1439.83 |
Net Assets of Lisata Therapeutics Inc. (1990–2025)
Net assets of Lisata Therapeutics Inc. from 1990 to 2025. This chart illustrates how Lisata Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See Lisata Therapeutics Inc. balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Lisata Therapeutics Inc. (1990–2025)
The table below shows the annual net assets of Lisata Therapeutics Inc. from 1990 to 2025. For live market cap and overall valuation, see Lisata Therapeutics Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $14.60 Million | -50.20% |
| 2024-12-31 | $29.32 Million | -38.79% |
| 2023-12-31 | $47.89 Million | -27.79% |
| 2022-12-31 | $66.32 Million | -27.91% |
| 2021-12-31 | $92.00 Million | +185.34% |
| 2020-12-31 | $32.24 Million | +56.87% |
| 2019-12-31 | $20.55 Million | -45.12% |
| 2018-12-31 | $37.45 Million | -25.38% |
| 2017-12-31 | $50.19 Million | +1134.23% |
| 2016-12-31 | $4.07 Million | -82.54% |
| 2015-12-31 | $23.28 Million | -59.91% |
| 2014-12-31 | $58.07 Million | -6.37% |
| 2013-12-31 | $62.03 Million | +88.99% |
| 2012-12-31 | $32.82 Million | -59.04% |
| 2011-12-31 | $80.13 Million | -7.35% |
| 2010-12-31 | $86.49 Million | +45.15% |
| 2009-12-31 | $59.59 Million | +6803.22% |
| 2008-12-31 | $863.18K | -73.97% |
| 2007-12-31 | $3.32 Million | +1035.27% |
| 2006-12-31 | $292.11K | +116.07% |
| 2005-12-31 | $-1.82 Million | +5.91% |
| 2004-12-31 | $-1.93 Million | -28.55% |
| 2003-12-31 | $-1.50 Million | -82.40% |
| 2002-12-31 | $-823.89K | -320.45% |
| 2001-12-31 | $373.73K | -88.06% |
| 2000-12-31 | $3.13 Million | -20.17% |
| 1999-12-31 | $3.92 Million | +1374.31% |
| 1998-12-31 | $-307.81K | +52.77% |
| 1996-12-31 | $-651.71K | -104.23% |
| 1995-12-31 | $-319.11K | +89.00% |
| 1994-12-31 | $-2.90 Million | -- |
| 1993-12-31 | $0.00 | -- |
| 1990-12-31 | $-700.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lisata Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55175200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Lisata Therapeutics Inc. Net Assets Breakdown (December 2025)
Lisata Therapeutics Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.06% |
| Other Comprehensive Income | $-37.00K | -0.25% |
| Other Components | $579.53 Million | 3901.28% |
| Total Equity | $14.86 Million | 100.00% |
Lisata Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Lisata Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Energisme
PA:ALNRG
|
$11.45 Million |
|
Regenbogen AG
F:RGB
|
$11.46 Million |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
$11.47 Million |
|
Daewoo SBI SPAC 1
KQ:215480
|
$11.47 Million |
|
Minbos Resources Ltd
AU:MNB
|
$11.45 Million |
|
Ecocab Co. Ltd
KQ:128540
|
$11.45 Million |
|
Vishwaraj Sugar Industries Limited
NSE:VISHWARAJ
|
$11.45 Million |
|
Prodigy Gold NL
AU:PRX
|
$11.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lisata Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,571,000 to 14,855,000, a change of -14,716,000 (-49.8%).
- Net loss of 16,586,000 reduced equity.
- New share issuances of 844,000 increased equity.
- Other comprehensive income increased equity by 44,000.
- Other factors increased equity by 982,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.59 Million | -111.65% |
| Share Issuances | $844.00K | +5.68% |
| Other Comprehensive Income | $44.00K | +0.3% |
| Other Changes | $982.00K | +6.61% |
| Total Change | $- | -49.76% |
Book Value vs Market Value Analysis
This analysis compares Lisata Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $-2489.63 | $1.09 | x |
| 1993-12-31 | $-2074.69 | $1.09 | x |
| 1994-12-31 | $-12033.20 | $1.09 | x |
| 1995-12-31 | $-19944.06 | $1.09 | x |
| 1996-12-31 | $-40731.81 | $1.09 | x |
| 1998-12-31 | $-19237.94 | $1.09 | x |
| 1999-12-31 | $47257.90 | $1.09 | x |
| 2000-12-31 | $21155.94 | $1.09 | x |
| 2001-12-31 | $2525.22 | $1.09 | x |
| 2002-12-31 | $-5529.50 | $1.09 | x |
| 2003-12-31 | $-8587.28 | $1.09 | x |
| 2004-12-31 | $-8904.30 | $1.09 | x |
| 2005-12-31 | $-5477.45 | $1.09 | x |
| 2006-12-31 | $210.91 | $1.09 | x |
| 2007-12-31 | $1514.94 | $1.09 | x |
| 2008-12-31 | $213.82 | $1.09 | x |
| 2009-12-31 | $2857.48 | $1.09 | x |
| 2010-12-31 | $1413.67 | $1.09 | x |
| 2011-12-31 | $1050.12 | $1.09 | x |
| 2012-12-31 | $359.53 | $1.09 | x |
| 2013-12-31 | $457.72 | $1.09 | x |
| 2014-12-31 | $267.96 | $1.09 | x |
| 2015-12-31 | $73.33 | $1.09 | x |
| 2016-12-31 | $11.19 | $1.09 | x |
| 2017-12-31 | $84.47 | $1.09 | x |
| 2018-12-31 | $58.41 | $1.09 | x |
| 2019-12-31 | $30.24 | $1.09 | x |
| 2020-12-31 | $31.58 | $1.09 | x |
| 2021-12-31 | $25.01 | $1.09 | x |
| 2022-12-31 | $12.85 | $1.09 | x |
| 2023-12-31 | $5.96 | $1.09 | x |
| 2024-12-31 | $3.55 | $1.09 | x |
| 2025-12-31 | $1.71 | $1.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lisata Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -111.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9756.47%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.19x
- Recent ROE (-111.65%) is above the historical average (-190.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | 0.00% | -60.22% | 1.36x | 0.00x | $-2.65 Million |
| 1994 | 0.00% | -16.01% | 2.15x | 0.00x | $-3.08 Million |
| 1995 | 0.00% | 0.00% | 0.00x | 0.00x | $1.74 Million |
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $-267.43K |
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | $-302.22K |
| 1999 | -28.36% | -8653.62% | 0.00x | 1.32x | $-1.50 Million |
| 2000 | -64.74% | -381.19% | 0.12x | 1.47x | $-2.34 Million |
| 2001 | -543.97% | -1892.10% | 0.06x | 4.91x | $-2.07 Million |
| 2002 | 0.00% | -1425.77% | 0.07x | 0.00x | $-1.08 Million |
| 2003 | 0.00% | -1615.52% | 0.21x | 0.00x | $-893.87K |
| 2004 | 0.00% | -3600.36% | 0.49x | 0.00x | $-1.56 Million |
| 2005 | 0.00% | -4948.78% | 0.05x | 0.00x | $-1.56 Million |
| 2006 | -2071.52% | -13233.75% | 0.04x | 4.09x | $-6.08 Million |
| 2007 | -314.98% | -4508.89% | 0.06x | 1.14x | $-10.78 Million |
| 2008 | -1070.71% | -11062.92% | 0.05x | 2.11x | $-9.33 Million |
| 2009 | -105.53% | -226.29% | 0.11x | 4.28x | $-28.65 Million |
| 2010 | -47.90% | -33.38% | 0.49x | 2.94x | $-28.17 Million |
| 2011 | -75.99% | -469.00% | 0.06x | 2.50x | $-53.34 Million |
| 2012 | -165.12% | -382.29% | 0.26x | 1.64x | $-58.10 Million |
| 2013 | -62.33% | -265.74% | 0.16x | 1.44x | $-45.24 Million |
| 2014 | -93.78% | -305.89% | 0.14x | 2.16x | $-60.72 Million |
| 2015 | -341.10% | -359.69% | 0.39x | 2.41x | $-83.26 Million |
| 2016 | -668.64% | -92.55% | 0.68x | 10.61x | $-33.14 Million |
| 2017 | 45.50% | 0.00% | 0.00x | 1.25x | $17.93 Million |
| 2018 | -42.85% | 0.00% | 0.00x | 1.18x | $-19.94 Million |
| 2019 | -96.57% | 0.00% | 0.00x | 1.30x | $-22.18 Million |
| 2020 | -25.08% | 0.00% | 0.00x | 1.11x | $-11.40 Million |
| 2021 | -29.77% | 0.00% | 0.00x | 1.05x | $-36.69 Million |
| 2022 | -81.45% | -44.68% | 1.66x | 1.10x | $-60.88 Million |
| 2023 | -43.28% | 0.00% | 0.00x | 1.14x | $-25.65 Million |
| 2024 | -67.58% | -1998.50% | 0.03x | 1.18x | $-22.94 Million |
| 2025 | -111.65% | -9756.47% | 0.01x | 1.19x | $-18.07 Million |
Industry Comparison
This section compares Lisata Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lisata Therapeutics Inc. (LSTA) | $7.99 Million | 0.00% | 0.38x | $11.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more